hMLH1 and hMSH2 can be considered tumor suppressor genes, as both alleles must be inactivated in order to lose the mismatch repair (MMR) function. In this regard, it has been proposed that LOH at MMR loci is a common Knudson's second-hit mechanism in HNPCC patients. However, experimental evidence supporting this view is scarcely found in the literature. We have performed a comprehensive analysis of LOH in 45 HNPCC tumors carrying a germline alteration in MMR loci. Overall, we have detected LOH at MMR loci in 56% of the cases. However, up to 40% of the LOH events targeted the mutant allele, arguing against a second-hit role in these tumors. Interestingly, the age at diagnosis was significantly older in these patients. To explain this and previous data, we propose a dual role for LOH at MMR loci in HNPCC.
The great majority of germline mutations in HNPCC patients are found in hMLH1 and hMSH2 genes (Peltomaki and de la Chapelle, 1997) . A defective allele is not sufficient for tumor initiation and a somatic second-hit inactivating the remaining wild-type (wt) allele is required . In this respect, mismatch repair (MMR) genes can therefore be considered as classical tumor suppressor genes fitting the Knudson 'two-hit' hypothesis (Potocnik et al., 2001) . Alternative mechanisms for the somatic hit of the wildtype allele have been described, amongst them deleterious mutations (Leach et al., 1993; Papadopoulus et al., 1994) , promoter hypermethylation (Herman et al., 1998; Kuismanen et al., 2000) and loss of heterozygosity (LOH) (Hemminki et al., 1994; Lu et al., 1996; Tannergard et al., 1997) . However, the mechanisms of tumor initiation are not well characterized. For instance, few studies have addressed the contribution of somatic mutations, probably reflecting technical complexity. Some have reported a low frequency (0-12.5%) of somatic mutations at the hMSH2 locus (Lu et al., 1996; Potocnik et al., 2001; Yuen et al., 2002) , whereas others have suggested that they might be the predominant second-hit at this locus (Konishi et al., 1996) . Discrepancies could be attributed to the low number of HNPCC tumors involved in each study. Similarly, data regarding hMLH1 is scarcely found in the literature. Potocnik et al. (2001) found a somatic mutation in one out of four tumors analysed, whereas Yuen et al. (2002) failed to identify somatic mutation in nine tumors. Inactivation of the hMLH1 gene by epigenetic mechanisms was first reported as the primary mechanism for MSI-H in sporadic CRC (Kane et al., 1997; Cunningham et al., 1998; Herman et al., 1998; Veigl et al., 1998; Wheeler et al., 1999) . Several authors have described hypermethylation of the hMLH1 promoter in a significant proportion (17-46%) of HNPCC tumors (Cunningham et al., 1998; Herman et al., 1998; Kuismanen et al., 2000; Potocnik et al., 2001) , suggesting that it may represent a second-hit mechanism of somatic inactivation. However, other studies did not find evidence of hMLH1 promoter hypermethylation in HNPCC tumors (Wheeler et al., 2000) . Aberrant methylation of the hMSH2 promoter has not been described neither in HNPCC tumors nor in sporadic MSI-HCRC (Cunningham et al., 1998; Kuismanen et al., 2000) .
A significant frequency of LOH at the relevant MMR loci has been found in most HNPCC series analysed. However, the actual frequency of LOH at the hMLH1 and hMSH2 is very different among studies. For instance, LOH at chromosome 3p has been reported in 35-85% of all tumors with germline mutation in hMLH1 (Lu et al., 1996; Tannergard et al., 1997; Kuismanen et al., 2000; Potocnik et al., 2001; Yuen et al., 2002) . Similarly, LOH in chromosome 2p has been described in 14-50% of all tumors with a germline hMSH2 mutation (Konishi et al., 1996; Lu et al., 1996; Potocnik et al., 2001; Yuen et al., 2002) . Whether these differences are owing to the low number of tumors involved in each study, technical issues or a true biological characteristic of the sample is not known. Moreover, quite frequently, LOH analysis does not distinguish the actual allele that has been lost in the tumor sample. Therefore, the possibility that some LOH targeting the mutated allele had been mistaken by evidence of a second hit in previous studies does exist.
In the present study, we have performed a comprehensive analysis of LOH in a well-defined cohort of Spanish HNPCC tumors with germline alterations in MMR loci in order to define its contribution to somatic inactivation of the remaining wild-type allele. We have included a total of 45 tumors diagnosed in 44 patients from 34 HNPCC Spanish families in which a previous scanning of germline mutations at the MMR loci hMLH1, hMSH2 and hMSH6 had been performed. The scanning included the analysis of all coding sequences and intron/exon boundaries by DGGE, as well as the analysis of genomic rearrangements at the hMLH1 and hMSH2 loci by MLPA. DGGE analysis of the MMR genes has been reported previously (Caldes et al., 2002) . MLPA was performed with the MRC Kit P003 and P008 according to the supplier instructions (MRC-Holland). In all, 41 tumors were colorectal adenocarcinomas, two endometrial adenocarcinomas, one gastric carcinoma and one ovarian carcinoma. A total of 40 tumors were MSI-H and five were MSS. Pathological reports were available in 42 tumors. The average age of diagnosis was 47.2 years. Tumors were classified as right sided if they were located in ascending hepatic flexure or transverse colon, and left sided if located in splenic flexure, descending, sigmoid or rectum. According to this classification, 21 were right and 17 were left. With regard to Duke's stage, 21 were A þ B and 17 were C þ D. With respect to differentiation of the tumors, 13 were well-differentiated and 18 were moderately-poorly differentiated. A total of 32 tumors were diagnosed in patients with a germline alteration in hMLH1, either a pathogenic mutation (25) or a non-pathogenic change (7), whereas 13 tumors were diagnosed in patients with a germline alteration in hMSH2 (10 tumors with pathogenic mutation and 3 tumors with non-pathogenic change). Data is shown in Table 1 . We have considered frame-shift and splicing mutations as pathogenic alterations in all cases. In addition, we have considered five missense changes in hMLH (L612 H, R687W, Y684D, K716 M, A111 V) and one in-frame deletion in hMSH2 (2194-2196 del ACT) as pathogenic mutations, based on the following criteria:
Strong evidence of co-segregation with cancer. Abrogation of the corresponding MMR protein in the tumors. All tumors tested were MSI-H. Identified in Amsterdam I/II criteria families.
We cannot rule out the possibility that some of these changes are not true deleterious mutations, but neutral changes linked to an unidentified pathogenic alteration. However, for the purpose of LOH analysis, both situations are equally informative.
All 35 tumors with pathogenic germline mutations showed lack of expression of the corresponding MMR protein and also of subcomplex members.
Consequently, if MSH2 is abrogated also MSH6 is not expressed and the same holds true for MLH1 and PMS2. Normal expression of these proteins was observed in tumors with non-pathogenic changes, with the exception of tumor ID-18. Specific lack of expression of MSH6 was observed in this tumor, although we did not find any pathogenic germline mutation (Table 1) . We analysed LOH at the pertinent MMR locus in all tumors. For this purpose, tumor tissues were first sectioned and hematoxylin-eosin stained. A pathologist determined the proportion of tumor cells in each sample (only samples with more than 90% of tumor cells were included in the present analysis). Tumor DNA was isolated from the paraffin-embedded material by taking tissue punches (diameter, 0.6 mm) with a tissue microarrayer (Beecher) from tumor areas selected on the basis of a HE-stained slide, using a chelex extraction method (De Jong et al., 2004) . Tumor DNA was compared with DNA from peripheral blood lymphocytes (PBL) isolated according to the salting out procedure (Miller et al., 1998) . Figure 1 shows a representative DGEE-LOH analysis of patients carrying a germline mutation in hMLH1 or hMSH2. Overall, LOH was detected in 56% (25/45) of the cases. As we can see in Table 2 , high frequency of LOH was observed, regardless of the locus or mutation status. Of particular interest, similar LOH rates were observed in tumors with pathogenic mutations or non-pathogenic changes. Moreover, contrary to what was expected, up to 40% of the tumors with pathogenic mutation and LOH demonstrated selective loss of the mutant allele. No correlation between the type of pathogenic germline mutation and LOH targeting the mutant allele was observed. Loss of the mutant allele was observed in frame-shift (ID-12), splicing (ID-7) or missense (ID-20b) mutations, indistinctively (Table 1) .
Other authors have reported selective loss of the wt allele in all HNPCC tumors with LOH analysed. In an attempt to explain the poor correlation observed in our study, we investigated if there is any association between LOH and clinical-pathological features of the tumors. Data is shown in Tables 3 and 4. Differentiation grade was not related to LOH, neither in hMLH1 nor in hMSH2 related tumors. LOH was observed in 12 out of 18 A þ B and four out of 11 C þ D tumors. Selective loss of the mutant allele was observed both in A þ B and C þ D tumors. LOH at the hMLH1 gene was most common in right-sided tumors, whereas LOH at the hMSH2 was in left-sided tumors, but loss of the mutant allele was observed in both locations. Interestingly, loss of the wt allele was observed in 10 out of 13 tumors diagnosed under 50 years of age (76.9%) but only in two out of seven tumors diagnosed at older ages (28.6%, OR ¼ 8.3, P ¼ 0.05, Fisher's exact test). The average age at diagnosis was 40.8 years in tumors loosing the wt allele and 53 years in tumors loosing the mutant allele (P ¼ 0.029, Student's t-test). Correlation between early age at diagnosis and loss of the wt allele was observed both at the hMLH1 and hMSH2 loci. A strong correlation between early onset and right-sided tumors is well established (Lynch and de la Chapelle, 1999) . However, we did not observe preferential loss of the wt allele in right-sided tumors. To further exclude an association between location and loss of the wt allele, we performed a sub-analysis in five right side tumors diagnosed from 62 to 76 years of age. Of these, four had LOH but only one had lost the wt allele. Taken together, our analysis indicates that selective lost of wt Table 1 Microsatellite instability (MSI) analysis was performed in DNA from paired tumor and normal samples (PBL) using the Bethesda panel of five markers (D2S123, D5S346, D17S250, BAT 25 and BAT 26). PCR amplifications were performed with the HNPCC Microsatellite Instability Test (Roche Molecular Biochemicals. Cat No 2 041 901) according to the supplier instructions. Tumors were classified as MSI-H if at least two of the five markers showed instability, otherwise they were classified as MSS. Immunohistochemistry (IHC) analysis was performed with antibodies against MLH1 (clone G168-728; 1:50; BD Biosciences, NJ), PMS2 (clone A16-4; 1:50; BD Biosciences), MSH2 (clone GB-12; 1:100; Oncogene Research Products, San Diego, CA), and MSH6 (clone 44; 1:400; BD Biosciences) in a DAKO Techmate 500+automated tissue strainer, using standard protocols and procedures as indicated by the manufacturer. Expression was scored as positive (+) when showed nuclear staining in at least some tumor cells and negative (0/+) when the tumor cells stained negative with a positive lymphocytes internal control. We performed DGGE-LOH (Tannergard et al., 1997; de la Hoya et al., 1999) . If alleles were not discriminated by DGGE, we performed loss of heterozygosity (LOH) analysis by direct sequencing (tumor ID: 14a, 14b, 14c and 22). In cases of genomic rearrangements, LOH was analyzed by direct overlapping of MLPA profiles obtained in normal and tumoral DNA (tumor ID: 1, 25 and 29). To further confirm the loss of the mutant allele, size fragment analysis by conventional polyacrylamide gel electrophoresis was performed in tumor ID:32, in which a 12bp deletion was present. LOH was scored when total loss of one allele could be observed in tumor DNA by visual inspection 10a and 10b, both tumors belong to the same patient. b LOH analysis was performed in two informative loci. Loss of the mutant allele was observed in both loci, indicating that the two changes co-segregate in the same chromosome. pathogenic mutations; n non-pathogenic changes.
allele is associated with early onset of diagnosis, independently of the location or other pathological features. A Knudson's 'two-hit mechanisms' for loss of MMR function in HNPCC tumors has been postulated . In keeping with that, we and others have observed lack of expression of the corresponding MMR protein in tumors with germline mutations in these genes.
At least three alternative mechanisms leading to inactivation of the wt allele have been postulated in HNPCC: somatic mutations, epigenetic silencing and LOH. This is best illustrated in Figure 2a . The model does not predict the actual LOH rate observed in different series of HNPCC tumors, as it depends on the relative contribution of other inactivating mechanisms. However, loss of the wt allele should be observed in all LOH cases. Although widely accepted, experimental evidence supporting the second-hit LOH paradigm in HNPCC is scarce in the literature. Hemminki et al. (1994) reported LOH in six out of 17 tumors with a known germline mutation in hMLH1. In all six cases, the wt allele was lost. Tannergard et al. (1997) reported LOH at the same locus in six out of seven cases. Loss of the wt allele was reported in two tumors, but data on the remaining four cases was not provided, despite the fact that the analysis was able to distinguish alleles. Data on hMSH2 is even scarcer. Lu et al. (1996) found LOH in four out of eight tumors carrying a known germline mutation in this gene. Loss of the wt allele was reported in two of these cases. Others have studied LOH at the MMR loci in HNPCC (Kuismanen et al., 2000; Yuen et al., 2002) , but their analysis did not distinguish alleles and hence, cannot be considered as a formal proof of second-hit LOH. Nonetheless, loss of the germline mutated allele has never been reported.
In clear contrast, the data that we present in this study shows a sharply different scenario. First, the frequency of LOH at the hMLH1 and hMSH2 loci is high in HNPCC tumors, irrespective of the presence of a germline mutation. Second, LOH in mutation carriers is not always targeting the wt allele. On the contrary, up to 40% of the LOH events detected in the present study were targeting the mutant allele. Third, loss of the wt allele is more likely observed in younger patients. Taken together, the data indicates that at least in some cases, tumor cells may select LOH at these loci for reasons other than inactivating the wt allele. Clearly, our data does not fit in the second-hit LOH paradigm.
It is important to note that the second-hit model assumes that in those tumors with somatic mutation or epigenetic silencing, LOH encompassing the MMR loci If the probability of selecting pathway A differs with age (for instance, epigenetic silencing may be related with older ages), the models predict different effects of age at diagnosis in LOH studies.
The second-hit model predicts a decreased LOH rate in older patients, but selective lost of wt allele will be observed irrespective of the age at diagnosis. By contrast, the dual model does not predict a sharp decrease of LOH rate in older patients, but predicts that loss of mutant alleles will be more common in these patients. A priori, the progression model does not predict any effect of age at diagnosis in LOH (neither overall rate nor biased loss of a particular allele). will not occur later on in tumor progression. In our opinion, this phenomenon lacks biological plausibility. On the contrary, we believe that the key to understand our data (the loss of mutant alleles that we observe in some tumors) is the fact that LOH encompassing the MMR loci may occur as part of tumor progression (progression LOH). The model is outlined in Figure 2b . In this model, LOH is no longer a second-hit, but once the wt allele has been inactivated, LOH encompassing the MMR loci is selected by some tumors. For instance, LOH could be a hallmark for genetic deletions involving other genes besides hMLH1/hMSH2 that may contribute to cancer development. The model predicts random loss of alleles. The progression model explains the loss of mutant alleles, but does not consider the possibility of LOH acting as a second-hit. We think that there is no reason to exclude this possibility. For this reason, we propose a dual role for LOH at the MMR loci in HNPCC. The dual LOH model is outlined in Figure 2c . LOH serves as a second-hit in certain tumors. However, in those in which the wild-type allele has been inactivated by other mechanisms, LOH encompassing these loci can be selected in tumor progression. The dual model predicts biased LOH. Selective loss of the wt allele will be more common because it occurs in two circumstances: as a second-hit in some tumors and randomly in the remaining ones. Our data does not have statistical power to distinguish between the progression and dual models. We have detected loss of the wt allele in 60% of the cases. This is nicely explained by the dual model, but it is not statistically different from the 50% predicted by the progression model. However, we have shown that preferential loss of the wt allele is more commonly observed in younger patients. The dual but not the progression model can easily explain this tendency. This is because the relative contribution of distinct mechanisms to LOH may be modified by age (see Figure 2 ). For instance, epigenetic alterations are generally considered aging related. Indeed, an association between epigenetic silencing of hMLH1 gene an older age at diagnosis is well established in sporadic CRC . Consequently, it is conceivable that epigenetic silencing will be the prominent second-hit in older HNPCC patients but less common at younger ages. Conversely, LOH will act as a second-hit predominantly in younger patients. In turn, this could explain the findings of previous studies (presumably performed in young patients) that claimed selective loss of the wt allele. For these reasons, we think that the dual model is probably more accurate in reflecting the role of LOH at the MMR loci in HNPCC. Further studies in larger series should be performed to clarify these points.
Our hypothesis of a dual role for LOH has been supported by data derived from HNPCC tumors. However, we do not discard that it may give clues to interpret the role of LOH in other familial cancer susceptibility loci.
In other cancer susceptibility disorders, like hereditary breast/ovarian cancer, it has been postulated that LOH analysis can be useful to clarify the pathogenic role of some BRCA1 unclassified variants (Osorio et al., 2002) . Our data indicated that LOH analysis cannot distinguish between pathogenic and non-pathogenic changes in MMR genes.
In brief, firstly we have shown evidence that in HNPCC; the role of LOH at the MMR is not restricted to act as a Knudson's second hit. Secondly, we have shown evidences that selective loss of the wt allele may be associated with tumors diagnosed at early ages and finally, we propose a model to explain these observations.
